PUBLISHER: 360iResearch | PRODUCT CODE: 1608028
PUBLISHER: 360iResearch | PRODUCT CODE: 1608028
Human Chorionic Gonadotropin Market by Product (Naturally Extracted, Recombinant), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermia Treatment), End-User - Global Forecast 2025-2030
The Human Chorionic Gonadotropin Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.37 billion in 2024, and is projected to grow at a CAGR of 7.53%, to USD 2.11 billion by 2030.
Human Chorionic Gonadotropin (HCG) is a hormone produced during pregnancy by the placenta, playing a critical role in fetal development. In the market research context, HCG is observed for its commercial applications in fertility treatments, weight management therapies, and its diagnostic use in pregnancy tests. The necessity for HCG hinges on its application in assisting reproductive health, primarily through its use in assisted reproductive technologies (ART) like in-vitro fertilization (IVF). Its medical applications extend beyond fertility, as it's being researched in areas such as tumor detection and management due to its presence in certain cancer types. The end-use scope covers fertility clinics, research laboratories, pharmaceutical companies, and diagnostic centers.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 1.27 billion |
| Estimated Year [2024] | USD 1.37 billion |
| Forecast Year [2030] | USD 2.11 billion |
| CAGR (%) | 7.53% |
Key growth factors influencing the HCG market include the increasing prevalence of infertility, rising awareness regarding reproductive health, and advancements in biotechnology facilitating innovative treatment options. Additionally, the market is propelled by the growing demand for rapid diagnostic kits. A potential opportunity lies in expanding the scope of HCG applications in oncology and developing its formulations to address weight management, opening streams for therapeutic developments. However, challenges such as regulatory hurdles, ethical considerations, and the high cost of fertility treatments pose significant limitations, potentially restraining market growth. Even socio-cultural factors, including the stigma attached to fertility treatments, could dampen market adoption.
For innovation and business growth, focusing on research in precision medicine and the biochemical pathways of HCG to broaden its therapeutic applications could enhance market viability. Moreover, investing in cost-effective treatment methodologies and establishing strong collaborative networks among biotech firms, research institutes, and healthcare providers can extend market penetration. The nature of the HCG market is dynamic, with innovations in genetic research and biomanufacturing catalyzing potential evolution. Understanding consumer needs, leveraging emerging biotechnologies, and fostering ethical transparency can guide market actors towards sustainable growth and competitive advantage.
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Chorionic Gonadotropin Market
The Human Chorionic Gonadotropin Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising incidents of infertility among populations
- Growing investments in the development of fertility clinics
- Increasing awareness of fertility treatments
- Market Restraints
- High cost associated with human chorionic gonadotropin therapy
- Market Opportunities
- Advancements in recombinant technology
- Emergence of gonadotropin therapy in the healthcare sector
- Market Challenges
- Possible side effects of human chorionic gonadotropin therapy
Porter's Five Forces: A Strategic Tool for Navigating the Human Chorionic Gonadotropin Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Chorionic Gonadotropin Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Human Chorionic Gonadotropin Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Chorionic Gonadotropin Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Human Chorionic Gonadotropin Market
A detailed market share analysis in the Human Chorionic Gonadotropin Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Chorionic Gonadotropin Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Chorionic Gonadotropin Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Human Chorionic Gonadotropin Market
A strategic analysis of the Human Chorionic Gonadotropin Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Human Chorionic Gonadotropin Market, highlighting leading vendors and their innovative profiles. These include Biocare Medical, LLC, Bristol Myers Squibb Company, Cipla Limited, Ferring B.V., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kamia Biomedical Company, Lee Biosolutions, Inc., Life Medicare & Biotech Private Limited, Livzon Pharmaceutical Group Inc., Lupin Limited, Merck & Co., Inc., Prospec-Tany Technogene Ltd., Qingdao kangyuan Biopharmaceutical Group Co., Ltd., Sanzyme ( P ) Ltd., Scripps Laboratories, Inc., Sun Pharmaceutical Industries Ltd., and Sunrise International Labs Ltd..
Market Segmentation & Coverage
This research report categorizes the Human Chorionic Gonadotropin Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Product, market is studied across Naturally Extracted and Recombinant.
- Based on Therapeutic Area, market is studied across Female Infertility Treatment, Male Hypogonadism, and Oligospermia Treatment.
- Based on End-User, market is studied across Fertility Clinics and Research Institutions.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidents of infertility among populations
- 5.1.1.2. Growing investments in the development of fertility clinics
- 5.1.1.3. Increasing awareness of fertility treatments
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with human chorionic gonadotropin therapy
- 5.1.3. Opportunities
- 5.1.3.1. Advancements in recombinant technology
- 5.1.3.2. Emergence of gonadotropin therapy in the healthcare sector
- 5.1.4. Challenges
- 5.1.4.1. Possible side effects of human chorionic gonadotropin therapy
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Human Chorionic Gonadotropin Market, by Product
- 6.1. Introduction
- 6.2. Naturally Extracted
- 6.3. Recombinant
7. Human Chorionic Gonadotropin Market, by Therapeutic Area
- 7.1. Introduction
- 7.2. Female Infertility Treatment
- 7.3. Male Hypogonadism
- 7.4. Oligospermia Treatment
8. Human Chorionic Gonadotropin Market, by End-User
- 8.1. Introduction
- 8.2. Fertility Clinics
- 8.3. Research Institutions
9. Americas Human Chorionic Gonadotropin Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Human Chorionic Gonadotropin Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Human Chorionic Gonadotropin Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. Market Share Analysis, 2023
- 12.2. FPNV Positioning Matrix, 2023
- 12.3. Competitive Scenario Analysis
- 12.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. Biocare Medical, LLC
- 2. Bristol Myers Squibb Company
- 3. Cipla Limited
- 4. Ferring B.V.
- 5. Fresenius Kabi AG
- 6. Intas Pharmaceuticals Ltd.
- 7. Kamia Biomedical Company
- 8. Lee Biosolutions, Inc.
- 9. Life Medicare & Biotech Private Limited
- 10. Livzon Pharmaceutical Group Inc.
- 11. Lupin Limited
- 12. Merck & Co., Inc.
- 13. Prospec-Tany Technogene Ltd.
- 14. Qingdao kangyuan Biopharmaceutical Group Co., Ltd.
- 15. Sanzyme ( P ) Ltd.
- 16. Scripps Laboratories, Inc.
- 17. Sun Pharmaceutical Industries Ltd.
- 18. Sunrise International Labs Ltd.
LIST OF FIGURES
- FIGURE 1. HUMAN CHORIONIC GONADOTROPIN MARKET RESEARCH PROCESS
- FIGURE 2. HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 13. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 15. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 20. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 21. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. HUMAN CHORIONIC GONADOTROPIN MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. HUMAN CHORIONIC GONADOTROPIN MARKET DYNAMICS
- TABLE 7. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY NATURALLY EXTRACTED, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FEMALE INFERTILITY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY MALE HYPOGONADISM, BY REGION, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY OLIGOSPERMIA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 18. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 20. AMERICAS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 21. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 22. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 23. ARGENTINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 24. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 25. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 26. BRAZIL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 27. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 28. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 29. CANADA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 30. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 31. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 32. MEXICO HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 33. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 34. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 35. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 36. UNITED STATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 37. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 38. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 39. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 40. ASIA-PACIFIC HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 41. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 42. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 43. AUSTRALIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 44. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 45. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 46. CHINA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 47. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 48. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 49. INDIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 50. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 51. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 52. INDONESIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 53. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 54. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 55. JAPAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 56. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 57. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 58. MALAYSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 59. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 60. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 61. PHILIPPINES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 62. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 63. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 64. SINGAPORE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 65. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 66. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 67. SOUTH KOREA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 68. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 69. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 70. TAIWAN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 71. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 72. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 73. THAILAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 74. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 75. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 76. VIETNAM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 77. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 78. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 81. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 82. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 83. DENMARK HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 84. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 85. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 86. EGYPT HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 87. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 88. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 89. FINLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 90. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 91. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 92. FRANCE HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 93. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 94. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 95. GERMANY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 96. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 97. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 98. ISRAEL HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 99. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 100. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 101. ITALY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 102. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 103. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 104. NETHERLANDS HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 105. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 106. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 107. NIGERIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 108. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 109. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 110. NORWAY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 111. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 112. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 113. POLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 114. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 115. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 116. QATAR HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 117. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 118. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 119. RUSSIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 120. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 121. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 122. SAUDI ARABIA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 123. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 124. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 125. SOUTH AFRICA HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 126. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 127. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 128. SPAIN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 129. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 130. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 131. SWEDEN HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 132. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 133. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 134. SWITZERLAND HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 135. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 136. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 137. TURKEY HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 138. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 139. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 140. UNITED ARAB EMIRATES HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 141. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
- TABLE 142. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
- TABLE 143. UNITED KINGDOM HUMAN CHORIONIC GONADOTROPIN MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 144. HUMAN CHORIONIC GONADOTROPIN MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 145. HUMAN CHORIONIC GONADOTROPIN MARKET, FPNV POSITIONING MATRIX, 2023
